ArticleHaematologica2025

Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma.

Ryan T Bishop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.